ALK-Abello A/S Presents Phase 3 Data On House Dust Mite SLIT-Tablet At EAACI Annual Congress In Copenhagen
6/9/2014 9:21:37 AM
First sublingual allergy immunotherapy tablet with robust results in allergic rhinitis and allergic asthma. Data supports European regulatory filing in 2H 2014
Today, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) has presented key trial results on its new sublingual allergy immunotherapy tablet (SLIT-tablet) for house dust mite (HDM) respiratory allergic diseases at the 2014 Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI), in Copenhagen, Denmark.
Help employers find you! Check out all the jobs and post your resume.
comments powered by